Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

aducanumab

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Brain accumulation of the amyloid-β (Aβ) peptide is believed to be the initial event in the Alzheimer disease (AD) process. A… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
Is this relevant?
2019
2019
SUV ratios (SUVRs) are commonly used to quantify tracer uptake in amyloid-β PET. Here, we explore the impact of target and… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2018
2018
Aducanumab, a human-derived antibody targeting amyloid-β (Aβ), is in Phase 3 clinical trials for the treatment of Alzheimer’s… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2017
2017
The amyloid hypothesis has been the dominant framework for Alzheimer's disease (AD) research, including the development of anti… Expand
Is this relevant?
2017
2017
The limited number of treatment options has made Alzheimer's disease (AD) a challenging problem for clinicians and patients… Expand
Is this relevant?
2017
2017
Toxic amyloid beta oligomers (AβOs) are known to accumulate in Alzheimer’s disease (AD) and in animal models of AD. Their… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2016
Highly Cited
2016
Alzheimer’s disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain… Expand
Is this relevant?
2016
2016
Calcium homeostasis plays a major role in maintaining neuronal function under physiological conditions. Amyloid-β (Aβ) initiates… Expand
Is this relevant?
2016
2016
Introduction Aducanumab (BIIB037), a human monoclonal antibody selective for aggregated forms of amyloid beta, is being… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2016
2016
At the 8th International Conference on Clinical Trials in Alzheimer's Disease held November 5-7, 2015 in Barcelona, Spain… Expand
Is this relevant?